FDA MAHARASHTRA

Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Date : 19/12/2016

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.
(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/KD/51298/2016/11/17570**

On the basis of the inspection carried out on **10/10/2016 & 06/12/2016** ,we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **MEDIBIOS LABORATORIES PVT. LTD.**
   Address : **PLOT NO. J-76, M.I.D.C., TARAPUR, BOISAR, THANE 401506 MAHARASHTRA STATE INDIA**
2. Licence No. : **KD276 In Form 25, KD226 In Form 28**

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
1	Capsules	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
2	Oral Powders / Granules / Pellets	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
3	Tablets	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance

No 40474

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 13 Dec 2018 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

INDIAN MERCHANTS' CHAMBER MUMBAI-INDIA 28 DEC 2016

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.
Maharashtra,INDIA.
Tel: +91-22-26592363/64
Fax: +91-22-26591958
1DEM106512982016121 4

Name of the Authorised person : O S SADHWANI

Signature :

Stamp and Date : Joint Commissioner (HQ) & Controlling Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:14 Dec 2016

COMMISSIONER, FOOD AND DRUG ADMINISTRATION

ATTESTED
AUTHORISED SIGNATORY
INDIAN MERCHANTS' CHAMBER
MUMBAI-INDIA

CERTIFIED TRUE COPY

ASHOK M. PANDYA
ADVOCATE & NOTARY (GOVT. OF INDIA)
C-6, Diamond Apts, Behind Diamond Cinema, L. T. Road, Borivali (W), Mumbai – 400 092.

14 DEC 2016

Explanatory notes

1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.

2. The certification number should be traceable within the regulatory authority issuing the certificate.

3. Where the regulatory authority issues a licence for the site , this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.

4. Table 1
List the dosage forms, starting materials, categories and activities. Examples are given below.

Example -1

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Dosage form (s)		
Tablets	Cytotoxic	Packaging
	Hormone	Production, Packaging, Quality control.
Injectables	Penicillin	Repackaging & Labelling.
	Cefalosporin	Aseptic preparation, Packaging, Labelling.

Example - 2.

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Starting material (s)2		
Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available. International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.

6. The requirements for good prac... the certificate are those include... guidelines and related materia... 1999. World Health Organizatio...



The Ministry of External Affairs does not responsible for Contents of the above document